ÐÓ°ÉÔ­´´

Charm Therapeutics shows promise by combining deep learning with 3D molecular structures to develop treatments for harmful proteins. This method offers a significant improvement over traditional drug discovery techniques, which are often slower and less accurate. By leveraging advanced AI, Charm Therapeutics can speed up the development of effective treatments, potentially reducing patient suffering. Their B2B model ensures steady partnerships and revenue from pharmaceutical companies aiming to expedite drug development. With backing from investors like Khosla Ventures and General Catalyst, Charm Therapeutics is well-positioned to make impactful advancements in health technology and biotech.